Lexicon Pharma (NASDAQ: LXRX) announced that it has completed enrollment in TELESTAR, its pivotal Phase 3 clinical trial of telotristat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE